A scheme to tackle the dilemma from hepatoma cells under doxorubicin-resistant surroundings: a brightness or a silhouette
Artificial Cells, Nanomedicine, and Biotechnology · Published 2026-07-21 · DOI 10.1080/21691401.2026.2694920
Free full text
Authors (6)
Ki-Kwang Oh, Goo-Hyun Kwon, Jung-A Eom, Kyeong Jin Lee, Dong Joon Kim, Ki-Tae Suk
Abstract
Background The aim of this study was to investigate key target(s), mechanism(s) from hepatoma cells in harsh doxorubicin-resistant conditions (DRCs) from GSE125180 datasets in GEO (Gene Expression Omnibus).Methods The identified components can be denoted as a brightness (therapeutic mark) or darkness (resistant mark) in DRCs. The protein-protein interaction (PPI) networks were assembled to identify the relationships between upregulated and downregulated genes via STRING, and R program.Results In the |log2 FC| > 1, and |log2 FC| > 2 subgroups, the uppermost target was a non-receptor tyrosine kinase (SRC) downregulated in DRCs, indicating that the dampened SRC is a therapeutic mark by doxorubicin (DOX). In contrast, in the |log2 FC| > 3 subgroup, the most significant target was Cluster of Differentiation 93 (CD93) upregulated in DRCs, suggesting that the overexpressed CD93 is a resistant mark in DRCs. Metoclopramide (MET) @ CD93 + DOX conformer is a highlighted capture to illuminate as combination therapy to overcome DRCs because MET is an inhibitor against CD93 as well as a non-competitive inhibitor on (MET @ CD93 + DOX) conformer.Conclusions These findings provide a mechanistic rationale for repurposing MET as an adjuvant agent to enhance therapeutic efficacy and overcome drug resistance in combination treatment strategies.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Publication details
- Year
- 2026
Citation
Oh, K., Kwon, G., Eom, J., et al. (2026). A scheme to tackle the dilemma from hepatoma cells under doxorubicin-resistant surroundings: a brightness or a silhouette. Artificial Cells, Nanomedicine, and Biotechnology. https://doi.org/10.1080/21691401.2026.2694920
Related articles
- Molecular mechanisms of phytochemicals from Zanthoxylum nitidum (Roxb.) DC. against hepatocellular carcinoma: insights from network pharmacology, molecular docking, and bioinformatics · Artificial Cells, Nanomedicine, and Biotechnology · 2026 · Same journal
- Antimicrobial properties and bioactivity of zirconia-based biocomposites · Artificial Cells, Nanomedicine, and Biotechnology · 2025 · Same journal
- Human tendon stem/progenitor cell-derived extracellular vesicle production promoted by dynamic culture · Artificial Cells, Nanomedicine, and Biotechnology · 2025 · Same journal
- Characterization of genipin-crosslinked gelatin/PVA hydrogels and the chondroprotective influence of hydroxytyrosol: an In vitro study · Artificial Cells, Nanomedicine, and Biotechnology · 2026 · Same journal
- Identification of mitophagy-related biomarkers in human rheumatoid arthritis using machine learning models · Artificial Cells, Nanomedicine, and Biotechnology · 2025 · Same journal
- Multi-omics analysis of the potential association between ageing and rheumatoid arthritis and screening of potential therapeutic targets · Artificial Cells, Nanomedicine, and Biotechnology · 2025 · Same journal
- Cross-talk between diabetic nephropathy and bone loss: PBMCs-guided discovery of NLRP3-inflammatory signalling · Artificial Cells, Nanomedicine, and Biotechnology · 2025 · Same journal
- Exosome-mediated perturbation of the immune-bone metabolism axis: a mechanistic investigation into bone loss in a simulated microgravity environment · Artificial Cells, Nanomedicine, and Biotechnology · 2025 · Same journal
- Bio-Inspired lipid nanovesicles (iNVs) incorporating membrane proteins from healthy tendon stem cells for targeted protein restoration in tendinopathic in vitro model · Artificial Cells, Nanomedicine, and Biotechnology · 2026 · Same journal
- Novel anti-rheumatic potential of Eucalrobusone C: inhibition of rheumatoid arthritis fibroblast-like synoviocytes and metabolic reprogramming · Artificial Cells, Nanomedicine, and Biotechnology · 2026 · Same journal